Development and characterization of multidrug resistant human hepatocarcinoma cell line in nude mice

Table 1 Sensitivity of in vitro and in vivo HepG2 and HepG2/ADM tumor cells to chemotherapeutic agents (mean ± SD)

Drug	IC50 values (mg/L)				RIa	RIb
	HepG2	HepG2/ADM	HepG2/nude	HepG2/ADM/nude
ADM	0.02 ± 0.015	1.02 ± 0.326b	0.16 ± 0.015	4.21 ± 0.012d	51.00	26.31
VCR	0.18 ± 0.011	10.27 ± 2.415b	0.18 ± 0.211	1.11 ± 0.075d	57.06	6.17
CDDP	0.87 ± 0.023	2.03 ± 0.360	0.22 ± 0.023	1.42 ± 0.032d	2.33	6.45
5-FU	9.48 ± 0.112	14.16 ± 1.924	0.53 ± 0.112	2.17 ± 0.670	1.49	4.09

HepG2/nude: HepG2 tumor in nude mice; HepG2/ADM/nude: HepG2/ADM tumor in nude mice; RI_a: Resistant index between HepG2 and HepG2/ADM; RI_b: Resistant index between HepG2/nude and HepG2/ADM/nude.

^bP < 0.01 vs HepG2;

^dP < 0.01 vs HepG2/nude.

Table 2 Levels of resistance-associated proteins in HepG2 and HepG2/ADM cells (mean ± SD)

Tumor cell	P-gp	MRP	LRP
HepG2	1.00 ± 0.04	0.16 ± 0.10	0.001 ± 0.00
HepG2/ADM	4.68 ± 0.63b	1.40 ± 0.15b	0.785 ± 0.04
HepG2/nude	1.00 ± 0.04	0.16 ± 0.08	0.001 ± 0.00
HepG2/ADM/nude	4.73 ± 0.68d	1.43 ± 0.16d	0.771 ± 0.02

^bP < 0.01 vs HepG2;

^dP < 0.01 vs HepG2/nude.